801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsSmall Volume Parenteral

Irinotecan Hydrochloride Injection Therapy For Metastatic Colorectal Cancer

Irinotecan Hydrochloride Injection Therapy For Metastatic Colorectal Cancer

Irinotecan Hydrochloride Injection Therapy For Metastatic Colorectal Cancer

Product Details:

Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: 40mg/2ml,100mg/5ml

Payment & Shipping Terms:

Minimum Order Quantity: 2000 vials
Price: Negotiation
Packaging Details: 10 vials/box
Delivery Time: 45days
Payment Terms: L/C, T/T
Supply Ability: 50, 000 vials per
Contact Now
Detailed Product Description
Product: Irinotecan Hydrochloride Injection Specification: 40mg/2ml,100mg/5ml
Standard: BP, USP Packing: 10 Vials/box

Irinotecan Hydrochloride Injection For Metastatic Colorectal Cancer

 

 

Product : Irinotecan Hydrochloride Injection

Specification : 40mg/2ml,100mg/5ml

Standard : BP, USP

Packing : 10 vials/box

 

Description :

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015.

 

Indication and Dosage

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

To treat colorectal cancer: 125 mg/m2 I.V. over 90 min every wk for 4 wk, followed by 2 wk of no drug, then repeat 6-wk cycle; or 350 mg/m2 I.V. over 90 min every 3 wk

 

Pharmacodynamics

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a semisynthetic derivative of camptothecin. Camptothecins interact specifically with topoisomerase I, an enzyme in the cell nucleus that regulates DNA topology and facilitates nuclear processes such as DNA replication, recombination, and repair. During these processes, topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks, allowing single DNA strands to pass through the break. The 3'-DNA terminus of the broken DNA strands bind covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After the DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the chemically unaltered topoisomers that allow transcription to proceed. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

 

Mechanism of action

Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Luke Liu

Send your inquiry directly to us (0 / 3000)